Mutational analysis of PDGFR–RAS/MAPK pathway activation in childhood medulloblastoma

• Published in: European journal of cancer (1990) Vol. 42; no. 5; pp. 646 - 649
• Main Authors: Gilbertson, Richard J., Langdon, Jaqueline A., Hollander, Andrew, Hernan, Roberto, Hogg, Twala L., Gajjar, Amar, Fuller, Christine, Clifford, Steven C.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.03.2006; Elsevier
• Subjects: Adolescent; Adult; Biological and medical sciences; BRAF; Cerebellar Neoplasms - genetics; Child; Child, Preschool; Exons; Female; Genes, ras - genetics; Humans; Infant; Male; MAP Kinase Signaling System; Medical sciences; Medulloblastoma; Medulloblastoma - genetics; Mitogen-Activated Protein Kinases - genetics; Mutation - genetics; PDGFR; Pharmacology. Drug treatments; Polymorphism, Restriction Fragment Length; RAS; Receptor, Platelet-Derived Growth Factor alpha - genetics; Receptor, Platelet-Derived Growth Factor alpha - metabolism; Receptors, Platelet-Derived Growth Factor - genetics; Tumors; PDGFR; BRAF; RAS; Medulloblastoma; Human; Platelet derived growth factor receptor; Enzyme; Mitogen-activated protein kinase; Pharmacology; BRAF Gene; Cancerology; C-Onc gene; Genetics; Medulloblastoma PDGFR BRAF RAS; Mutation; Child; Protooncogene

Aberrant signalling via platelet derived growth factor receptors (PDGFRs) and the RAS/MAPK pathway has been implicated in the development of medulloblastoma, the most common malignant brain tumour in childhood. To determine whether genetic mechanisms play a role in the activation of PDGFR–RAS/MAPK s...